Characterization of  AQX ‐1125, a small‐molecule  SHIP1  activator | Zendy

Stenton Grant R | Zendy; Mackenzie Lloyd F | Zendy; Tam Patrick | Zendy; Cross Jennifer L | Zendy; Harwig Curtis | Zendy; Raymond Jeffrey | Zendy; Toews Judy | Zendy; Wu Joyce | Zendy; Ogden Nancy | Zendy; MacRury Thomas | Zendy; Szabo Csaba | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Characterization of AQX ‐1125, a small‐molecule SHIP1 activator

Author(s) -

Stenton Grant R,

Mackenzie Lloyd F,

Tam Patrick,

Cross Jennifer L,

Harwig Curtis,

Raymond Jeffrey,

Toews Judy,

Wu Joyce,

Ogden Nancy,

MacRury Thomas,

Szabo Csaba

Publication year - 2013

Publication title -

british journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.432

H-Index - 211

eISSN - 1476-5381

pISSN - 0007-1188

DOI - 10.1111/bph.12039

Subject(s) - cytokine , chemotaxis , activator (genetics) , in vivo , pharmacology , phosphorylation , chemistry , protein kinase b , microbiology and biotechnology , biology , biochemistry , immunology , receptor

The SH2-containing inositol-5'-phosphatase 1 (SHIP1) metabolizes PI(3,4,5)P3 to PI(3,4)P2. SHIP1-deficient mice exhibit progressive inflammation. Pharmacological activation of SHIP1 is emerging as a potential therapy for pulmonary inflammatory diseases. Here we characterize the efficacy of AQX-1125, a small-molecule SHIP1 activator currently in clinical development.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research